GlassScriptPhysician profile
Maha A Daimee
NPI 1528455383
$83,265.09
in general payments reported to CMS, 2019-2025
29 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $46.66 · 2021: $388 · 2022: $169 · 2023: $604 · 2024: $778 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,582.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $80,000.00 | 2019 | |
| Abbvie INC. | $312.56 | 2022-2025 | |
| Emd Serono, INC. | $303.74 | 2023-2025 | Mavenclad |
| Pfizer INC. | $295.82 | 2021-2025 | |
| Ucb, INC. | $268.18 | 2021-2025 | Rystiggo, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $237.28 | 2021-2025 | |
| Eisai INC. | $222.13 | 2024-2025 | |
| Celgene Corporation | $199.62 | 2023-2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $194.67 | 2023-2025 | Nuedexta, Rexulti |
| Kyowa Kirin, INC. | $162.88 | 2021 | |
| Harmony Biosciences LLC | $139.33 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $136.82 | 2025 | Uzedy, Austedo Xr |
| Lilly USA, LLC | $101.49 | 2023-2025 | Kisunla, Emgality, Amyvid |
| E.R. Squibb & Sons, L.L.C. | $95.40 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $84.36 | 2023-2025 | Symbravo, Sunosi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $68.50 | 2020-2025 | |
| Becton, Dickinson and Company | $62.97 | 2019-2021 | |
| Banner Life Sciences, LLC | $54.00 | 2021 | |
| Horizon Therapeutics Plc | $48.67 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $44.89 | 2025 | Ponvory |
| Genzyme Corporation | $37.83 | 2021-2022 | |
| Genentech USA, INC. | $35.48 | 2019-2021 | |
| Amgen INC. | $30.43 | 2025 | Uplizna |
| Sk Life Science, INC. | $24.61 | 2020 | |
| Neurelis, INC. | $22.92 | 2023 | Valtoco |
| Alexion Pharmaceuticals, INC. | $20.37 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.27 | 2024 | Horizant |
| Tanabe Pharma America, INC. | $20.07 | 2025 | Radicava |
| Lundbeck LLC | $19.80 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maha Daimee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.